Penumbra INC 10-Q quarterly reports

Penumbra, Inc. announces robust revenue growth in Q2 2026, driven by strong performance in thrombectomy and embolization products, while progressing towards its acquisition by Boston Scientific.

Penumbra, Inc. reported a 15.6% increase in revenue for the first quarter of 2026, driven by strong performance in thrombectomy and embolization products, while preparing for its acquisition by Boston Scientific.

Penumbra, Inc. reported a significant increase in revenue and net income for the third quarter and first nine months of 2025, driven by strong sales of its thrombectomy and embolization and access products.

Penumbra, Inc. announced a significant return to profitability and robust revenue growth in its second quarter and first half of 2025, driven by strong U.S. sales and improved gross margins.

Penumbra Inc. announces a 16.3% increase in revenue for Q1 2025, primarily driven by strong sales of its thrombectomy products.

Penumbra Inc. reported its third quarter 2024 results, including a strategic decision to exit its Immersive Healthcare business, impacting financials with impairment charges and restructuring costs.

Penumbra Inc. reported a net loss for the second quarter of 2024, impacted by a significant impairment charge related to its Immersive Healthcare business, despite revenue growth in its thrombectomy product line.

Penumbra, Inc. saw a 15.4% increase in revenue in the first quarter of 2024, primarily driven by strong sales of its thrombectomy products.